Login / Signup
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game.
Xavier Roblin
Stephane Paul
Stéphane Nancey
Published in:
Alimentary pharmacology & therapeutics (2021)
Keyphrases
</>
rheumatoid arthritis
ulcerative colitis
patients with inflammatory bowel disease
combination therapy
replacement therapy